SLNO Rasio cepet Soleno Therapeutics

Soleno Therapeutics' focus on rare metabolic pathologies with minimal environmental impact is visualized on the GURU.Markets platform; this chart clearly demonstrates solvency via the quick ratio. The value 5.08 determines this parameter level, confirming a market monopoly driven by orphan drug status. The scientific team's flexibility is ensured by the full outsourcing of production and clinical trials.

Quick liquidity measures a company's ability to instantaneously settle short-term obligations using exclusively cash and accounts receivable, excluding slow-moving inventories. For Soleno Therapeutics (SLNO), which is awaiting monopoly status in the Prader-Willi syndrome treatment niche, a liquidity check via the acid test is critical for assessing financial stability prior to drug commercialization, determining the risk of a sudden capital shortfall.